CAR T-cell therapy

Chimeric antigen receptors (CARs)

CARs

CAR T-cell toxicities

Neurological toxicities

Toxicity grading system

Supportive care

Tocilizumab

Indications for corticosteroids

Toxicity factors

Risk factors

Infection risk

Severe toxicity

NIH specific thresholds

B cell maturation antigen

Multiple myeloma

Multiple myeloma

Protocol design

B-cell maturation antigen

T cell engineering

Patient characteristics

Multiple myeloma reduction

Patient 14

Response summary

Anti-BCMA CAR T cells

Anti-BCMA CAR T-cell summary

Study CRB401

Bb2121 responses

Progression-free survival

Room for improvement

CARs with heavy chain only

Clinical trail

Demographics

Summary

Relapse

Future plans

Acknowledgements